A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Condition:   Castration-Resistant Prostatic Cancer Interventions:   Drug: Niraparib;   Drug: Abiraterone acetate (AA);   Drug: Prednisone;   Drug: Placebo for Niraparib Sponsor:   Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials